Mr William Robb, Consultant Bariatric and Upper Gastrointestinal Surgeon at Blackrock WeightCare, has consistently emphasised that revision surgery should not be viewed as failure. Obesity is a chronic, relapsing disease. Surgical intervention is powerful, but long-term disease progression, anatomical factors and evolving metabolic challenges may require reassessment.

Understanding revision bariatric surgery

Revision bariatric surgery refers to a secondary procedure performed after a previous weight loss operation. This may involve:

• Conversion of one procedure to another
• Correction of anatomical complications
• Surgical management of inadequate weight loss or weight regain
• Treatment of severe reflux or nutritional complications

Revision surgery is technically more complex than primary bariatric surgery and should be undertaken in experienced, high-volume centres.

When should GPs consider referral?

There are several clear clinical scenarios where referral for specialist reassessment is appropriate.

1. Significant weight regain

Some degree of weight regain can occur several years after bariatric surgery and does not automatically indicate surgical failure. However, substantial regain — particularly when accompanied by recurrence of comorbidities such as type 2 diabetes, hypertension or obstructive sleep apnoea – warrants specialist review.

In clinical practice, revision referrals most commonly follow sleeve gastrectomy. While sleeve surgery is highly effective for many patients, a subset may experience weight regain over time or develop anatomical changes such as sleeve dilation. In selected cases, conversion to another metabolic procedure may restore weight control and improve metabolic outcomes.

GPs should consider referral when:

• BMI rises significantly above the patient’s post-operative low
• Glycaemic control deteriorates after a period of remission
• Antihypertensive or diabetic medication burden begins to increase again

Early referral allows structured reassessment, including dietary review, behavioural factors, metabolic evaluation and, where appropriate, imaging to assess anatomy.

2. Inadequate initial weight loss

A small proportion of patients may not achieve expected weight loss following primary surgery. This is again most frequently seen after sleeve gastrectomy, particularly in patients who began with higher BMI or severe metabolic disease.

In these cases, referral allows consideration of whether escalation to a more metabolically powerful procedure — such as gastric bypass or SADI-S — may be appropriate.

3. Persistent or severe reflux after sleeve gastrectomy

Gastro-oesophageal reflux disease is a recognised complication following sleeve surgery. Persistent reflux symptoms despite optimal medical therapy should prompt surgical evaluation.

Conversion from sleeve gastrectomy to gastric bypass is an established revisional strategy and can offer significant symptomatic relief in carefully selected patients.

Referral is appropriate when:

• Reflux remains uncontrolled despite proton pump inhibitors
• Endoscopic evidence of oesophagitis is present
• Barrett’s oesophagus develops or progresses

4. Complex or high BMI patients

Patients who began with BMI over 50, or those with severe metabolic disease, may occasionally require further intervention if initial weight loss has been insufficient.

Revisional bariatric surgery in these cases is technically complex and should be undertaken in experienced, high-volume centres with advanced minimally invasive or robotic capability.

Why experience matters in revision surgery

Revision bariatric surgery is inherently more complex than primary procedures. Previous surgery alters anatomy, creates adhesions and may change tissue planes. These factors require careful pre-operative planning and precise intraoperative technique.

Nutritional status, metabolic stability and psychological readiness must also be reassessed. Revision surgery is not simply a technical adjustment – it is a structured re-evaluation of a chronic disease pathway.

For this reason, revisional procedures are best undertaken in experienced, high-volume centres with advanced minimally invasive and robotic capability. Enhanced visualisation and instrument precision can be particularly valuable in complex cases where anatomy has already been modified.

Careful case selection, multidisciplinary discussion and structured follow-up remain central to safe and effective revision practice.

A collaborative approach with primary care

GPs play a pivotal role in long-term follow-up after bariatric surgery. Monitoring weight trajectory, glycaemic control, blood pressure and symptom progression allows early identification of patients who may benefit from reassessment.

Referral for revision surgery should not be interpreted as treatment failure. Obesity is a chronic metabolic condition. Disease progression, anatomical adaptation or evolving comorbidities may require adjustment of the original strategy.

At Blackrock WeightCare, referrals for revision assessment are welcomed via Healthlink. Each patient undergoes detailed review of previous operative history, current metabolic status, symptom profile and long-term goals before any recommendation is made.

The aim is always to restore metabolic control safely and appropriately.

Supporting your patients at the right time

GPs remain central to long-term care after bariatric surgery. When weight regain, relapse of diabetes or persistent reflux becomes apparent, early referral for reassessment can help prevent further progression.

Revision surgery is not about repeating the past, it is about adjusting the treatment pathway where needed.

At Blackrock WeightCare, every referral is reviewed carefully and individually. GPs can refer via Healthlink or contact the team directly to discuss a patient – 01 255 2479.

Your Health. We Care.

The post When should GPs consider referral for revision bariatric surgery appeared first on Blackrock WeightCare.

That’s the wrong question.

The right question is: what does this patient need, at this stage of their disease?

Obesity is chronic, progressive, and heterogeneous. The era of picking a lane — medical or surgical — is over. The best outcomes come from building integrated pathways. Here’s how I think we could think about it clinically.

BMI 27–35: Early intervention, metabolic protection

This is where the newer incretin therapies have genuinely expanded our toolkit. For patients without advanced complications, GLP-1s can achieve meaningful weight loss and delay progression to T2DM, NAFLD, and OSA. The goal here is prevention — getting in early before the disease accumulates damage. Medication earns its place at this stage, and I use it.

BMI 35–45: The judgment zone

No dogma here. This is where clinical decision making meets outcome data.

I’ll consider GLP-1s alone when diabetes is mild or very recently diagnosed and the patient is highly adherent. Endoscopic options when they want a lower-risk bridge with 15% total body weight loss (TBWL). Surgery when there’s severe GERD, significant visceral fat, liver fibrosis, established diabetes or a poor response to medical therapy.

Often the sequence is: surgery for the durability that drugs alone haven’t matched long-term. HbA1c, reflux burden, functional status, and what the patient can realistically sustain for 20 years, cumulative cost of injectables — these also can drive the decision for surgery versus a trial of medication, not the BMI alone.

BMI 45+: Surgery anchors the pathway

The data here hasn’t changed, and it won’t be overturned by a few years of GLP-1 trial data. For severe obesity with end-organ damage — fatty liver disease, refractory T2DM, sleep apnoea, joint destruction — metabolic surgery delivers weight loss and disease remission at a magnitude we cannot replicate pharmacologically with medications available to date. Not yet. Possibly not ever, for this cohort.

That said, GLP-1s have earned a genuine role around surgery: shrinking the liver pre-operatively in very high BMI patients, reducing anaesthetic risk, and rescuing for weight regain long after the operation. They can extend what surgery starts. They don’t replace what surgery does.

What the best programs are building

Stratify by more than BMI — we need to stratify patients by metabolic burden, genetics, psychological readiness, and social context all matter. Sequence therapies deliberately and consider what the correct combinations are based on the stage of the disease. Follow patients for decades, not months. And put surgeons, physicians, dietitians, and psychologists in the same room, sharing the same data.

The tribalism between “medical” and “surgical” camps has cost patients. The win here is designing systems that deliver the right option, to the right patient, at the right moment in their disease trajectory.

That’s precision obesity care. And it needs surgeons to build it.

Your Health. We Care.

The post Knife and Needles appeared first on Blackrock WeightCare.

Will the weight come back?

The honest answer is that weight regain can happen with both treatments. The difference lies in why it happens, how common it is, and how it is managed.

Understanding that difference matters before choosing your next step.

Why Weight Regain Happens After Injections

Medications such as Mounjaro and Ozempic work by regulating appetite hormones and slowing stomach emptying. While you are taking them, appetite is reduced and calorie intake falls.

The challenge is what happens when the medication stops.

These injections do not permanently change the anatomy of the digestive system. Once the medication is withdrawn:

• Appetite hormones gradually return to baseline
• Hunger increases
• Calorie intake rises
• Weight regain can occur

Clinical studies have shown that a significant proportion of weight lost on GLP-1 medications may be regained after stopping treatment if no structured long-term plan is in place.

This means injections need to be continued long term to maintain results. Medication is a lifelong treatment for a chronic disease. That carries a commitment to continuing the medications with clear cost implications and requires ongoing medical supervision.

Why Weight Regain Happens After Bariatric Surgery

Weight regain after surgery is different.

Procedures such as Gastric Sleeve and SADI-S permanently alter stomach size and, in some cases, nutrient absorption. They also create long-lasting hormonal changes that reduce hunger and improve insulin sensitivity.

However, surgery is not immune to weight regain.

Reasons may include:

• Gradual adaptation of the stomach over time
• High-calorie liquid intake
• Grazing behaviour
• Emotional eating
• Reduced follow-up engagement
• Lack of dietary structure

The key difference is that the anatomical and hormonal changes from surgery remain in place. This makes weight regain generally slower and often less dramatic than after stopping injections.

In most cases, surgery provides more durable long-term weight loss, particularly in patients with BMI over 45.

How Much Weight Regain Is Normal

After bariatric surgery, small amounts of weight regain several years later can be normal. The body stabilises after the initial weight loss phase. The goal is not zero regain. The goal is maintaining significant net weight loss and improvement in health.

After stopping injections, weight regain can be more rapid because the hormonal effect is removed entirely.

The pattern is different. The underlying biology explains why.

Which Offers More Durable Results

For patients with severe obesity, especially BMI above 40, bariatric surgery consistently shows stronger and more durable long-term outcomes compared to injections alone.

Injections can be effective for moderate obesity. They are valuable tools. But they do not currently match the long-term metabolic impact of surgery in higher BMI groups. That does not mean injections have no role. In some patients, they are appropriate as:

• A primary treatment
• A bridge before surgery
• Support in cases of mild post-surgical regain

For many patients the treatment of their obesity may involve both – often surgery now and medication later if ever required.

The decision depends on the individual.

What Happens if Weight Regain Occurs

At Blackrock WeightCare, weight regain is managed proactively.

This may include:

• Nutritional review
• Behavioural support
• Medical optimisation
• Use of medication where appropriate
• Consideration of revisional surgery in selected cases

Mr William Robb assesses each situation carefully. As an Upper GI and Robotic Bariatric Surgeon, he evaluates anatomical, metabolic and behavioural factors before recommending next steps.

The focus is always on long-term health, not short-term numbers.

The Bigger Question

The real question is not whether weight regain is possible. It is which treatment offers the most sustainable control of a chronic disease.

Obesity is a long term chronic disease. It requires a long-term plan and an ever evolving algorithm of care.

Injections require ongoing use to maintain effect. Surgery creates permanent anatomical and hormonal changes that support durability, particularly in higher BMI patients.

Neither is a quick fix. Both require commitment and follow-up.

Choosing the Right Path

If you are concerned about weight regain, whether after injections or surgery, the right step is expert assessment before making changes.

At Blackrock WeightCare, complex and high BMI patients are routinely assessed to determine the safest and most effective long-term strategy.

To know more, click here and fill the enquiry form or speak directly with our team on 01 255 2479.

Your Health. We Care.

The post Weight Regain After Injections vs Bariatric Surgery: What is the Difference appeared first on Blackrock WeightCare.